Pegoraro 2024 Adv Drug Deliv Rev: Difference between revisions

From Bioblast
(Created page with "{{Publication |title=Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ (2024) Unlocking the mitochondria for nanomedicine-based Treatments: Overcoming biological Barriers,...")
Β 
No edit summary
Line 1: Line 1:
{{Publication
{{Publication
|title=Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ (2024) Unlocking the mitochondria for nanomedicine-based Treatments: Overcoming biological Barriers, improving Designs, and selecting verification techniques.
|title=Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ (2024) Unlocking the mitochondria for nanomedicine-based treatments: overcoming biological barriers, improving designs, and selecting verification techniques.
|info=Adv Drug Deliv Rev [Epub ahead of print]. [https://www.ncbi.nlm.nih.gov/pubmed/38325562 PMID: 38325562 Open Access]
|info=Adv Drug Deliv Rev [Epub ahead of print]. [https://www.ncbi.nlm.nih.gov/pubmed/38325562 PMID: 38325562 Open Access]
|authors=Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ
|authors=Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ

Revision as of 16:59, 9 February 2024

Publications in the MiPMap
Has title::Pegoraro C, Domingo I, Conejos-SΓ‘nchez I, Vicent MJ (2024) Unlocking the mitochondria for nanomedicine-based treatments: overcoming biological barriers, improving designs, and selecting verification techniques.

Β» [[Has info::Adv Drug Deliv Rev [Epub ahead of print]. PMID: 38325562 Open Access]]

Was written by::Pegoraro C, Was written by::Domingo I, Was written by::Conejos-SΓ‘nchez I, Was written by::Vicent MJ (Was published in year::2024) Was published in journal::Adv Drug Deliv Rev

Abstract: [[has abstract::Enhanced targeting approaches will support the treatment of diseases associated with dysfunctional mitochondria, which play critical roles in energy generation and cell survival. Obstacles to mitochondria-specific targeting include the presence of distinct biological barriers and the need to pass through (or avoid) various cell internalization mechanisms. A range of studies have reported the design of mitochondrially-targeted nanomedicines that navigate the complex routes required to influence mitochondrial function; nonetheless, a significant journey lies ahead before mitochondrially-targeted nanomedicines become suitable for clinical use. Moving swiftly forward will require safety studies, in vivo assays confirming effectiveness, and methodologies to validate mitochondria-targeted nanomedicines' subcellular location/activity. From a nanomedicine standpoint, we describe the biological routes involved (from administration to arrival within the mitochondria), the features influencing rational design, and the techniques used to identify/validate successful targeting. Overall, rationally-designed mitochondria-targeted-based nanomedicines hold great promise for precise subcellular therapeutic delivery.]]

β€’ Bioblast editor: [[has editor::Plangger M]]


Labels: MiParea: MiP area::Respiration 





HRR: Instrument and method::Oxygraph-2k 

additional label::2024-02 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.